Egnyte Releases Quality Document Management Offering
Egnyte announced a new product for emerging life sciences companies to manage regulated documentation. Egnyte for Life Sciences Quality is a GxP-compliant product that digitizes the lifecycle of regulated documents, like standard operating procedures (SOPs) and training records. Egnyte for Life Sciences Quality is the third product in a growing lineup of offerings, following the release of Egnyte for Life Sciences in November 2020 and new review and approval workflows.
Egnyte for Life Sciences Quality enables Life Sciences companies to:
- Meet GxP & FDA 21 CFR Part 11
- Perform e-Signatures: sign off on documents, like SOPs and clinical trial protocols, in a compliant manner, without needing third-party plugins.
- Manage effective documents: as new versions are approved, Quality teams can define version numbers for new drafts, set expiry dates, and ensure only effective copies are available.
- Scale compliance processes quickly: built with best practices gleaned from 17,000 global customers, Egnyte for Life Sciences Quality implements and validates as it integrates with existing IT infrastructure.
- Support for multiple departments and use cases: designed with the ability to support training, continuity, and site readiness documentation.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
